Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in
subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy,
one of which was an Immune Checkpoint Inhibitor (ICI).